Adjunctive brexpiprazole in patients with major depressive disorder and irritability: An exploratory study

Journal of Clinical Psychiatry

Volumn 77, Issue 12, 2016, Pages 1695-1701

  Fava, Maurizio ^a   Mard, Franis ^b   Davidsen, Charlotte Kampp ^b   Baker, Ross A ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b H LUNDBECK A S   (Denmark)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREXPIPRAZOLE; ANTIDEPRESSANT AGENT; QUINOLONE DERIVATIVE; SEROTONIN RECEPTOR AFFECTING AGENT; THIOPHENE DERIVATIVE;

ADULT; AKATHISIA; ANGER; ANGER ATTACKS QUESTIONNAIRE; ANGER HOSTILITY SUBSCALE SCORE; ANXIETY; ARTICLE; ASTHENIA; ASTHMA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV-TR; EXPLORATORY RESEARCH; FALLING; FATIGUE; FEMALE; HEADACHE; HUMAN; IMPULSIVENESS; INCREASED APPETITE; INSOMNIA; INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY CLINICIAN VERSION; IRRITABILITY; KELLNER SYMPTOM QUESTIONNAIRE DEPRESSION SUBSCALE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE TOTAL SCORE; PANIC; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RESTLESSNESS; SEDATION; SHEEHAN IRRITABILITY SCALE; SIDE EFFECT; SOMNOLENCE; SYMPTOM; TREATMENT DURATION; WEIGHT GAIN; XEROSTOMIA; COMBINATION DRUG THERAPY; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG ADMINISTRATION; DRUG EFFECTS; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRRITABLE MOOD; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); QUINOLONES; SEROTONIN AGENTS; THIOPHENES;

EID: 85007595758     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15m10470     Document Type: Article

References (30)

1. Fava M, Hwang I, Rush AJ, et al. The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15(8):856-867. doi:10.1038/mp.209.20
2. Perlis RH, Fava M, Trivedi MH, et al. Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder. Acta Psychiatr Scand. 2009;119(4):282-289. doi:10.1/j.160-047.208.01298.x
3. Perlis RH, Fraguas R, Fava M, et al. Prevalence and clinical correlates of irritability in major depressive disorder: A preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. J Clin Psychiatry. 2005;66(2):159-166. doi:10.408/JCP.v6n0202
4. Fava M, Rosenbaum JF, McCarthy M, et al. Anger attacks in depressed outpatients and their response to fluoxetine. Psychopharmacol Bull. 1991;27(3):275-279.
5. Fava M, Rosenbaum JF. Anger attacks in patients with depression. J Clin Psychiatry. 1999;60(suppl 15):21-24.
6. Painuly N, Sharan P, Mattoo SK. Antecedents, concomitants and consequences of anger attacks in depression. Psychiatry Res. 2007;153(1):39-45. doi:10.1016/j.psychres.206.03.01
7. Farabaugh AH, Mischoulon D, Fava M, et al. The potential relationship between levels of perceived stress and subtypes of major depressive disorder (MDD). Acta Psychiatr Scand. 2004;110(6):465-470. doi:10.1/j.160-047.204.037.x
8. Tedlow J, Leslie V, Keefe BR, et al. Axis I and Axis II disorder comorbidity in unipolar depression with anger attacks. J Affect Disord. 1999;52(1-3):217-223. doi:10.1016/S0165-0327(98)074-3
9. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonindopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589-604. doi:10.124/jpet.14.213793
10. Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: A phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76(9):1224-1231. doi:10.408/JCP
11. Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: A phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76(9):1232-1240. doi:10.408/JCP.14m09689
12. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
13. Chandler GM, Iosifescu DV, Pollack MH, et al. RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010;16(5):322-325. doi:10.1/j.175-5949.209.0102.x
14. Montgomery SA, Sberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. doi:10.192/bjp.134.4.382
15. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised Edition. Washington, DC: US Department of Health, Education, and Welfare; 1976.
16. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDSSR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: A psychometric evaluation. Psychol Med. 2004;34(1):73-82. doi:10.1017/S032917030107
17. Desseilles M, Witte J, Chang TE, et al. Massachusetts General Hospital SAFER criteria for clinical trials and research. Harv Rev Psychiatry. 2013;21(5):269-274. doi:10.1097/HRP.0b013e3182a75c7
18. Khan SA, Revicki DA, Hassan M, et al. Assessing the reliability and validity of the Sheehan Irritability Scale in patients with major depressive disorder [published online ahead of print September 15, 2015]. J Clin Psychiatry. doi:10.408/JCP.14m09719
19. Kirby KN. One-year temporal stability of delaydiscount rates. Psychon Bull Rev. 2009;16(3):457-462. doi:10.3758/PBR.16.3.457
20. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt Impulsiveness Scale. J Clin Psychol. 1995;51(6):768-774. doi:10.102/1097-4679(1951)51:63.0.CO;2-1
21. Kellner R. A symptom questionnaire. J Clin Psychiatry. 1987;48(7):268-274.
22. Fava M, Iosifescu DV, Pedrelli P, et al. Reliability and validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire. Psychother Psychosom. 2009;78(2):91-97. doi:10.159/0201934
23. Baer L, Ball S, Sparks J, et al. Further evidence for the reliability and validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ). Ann Clin Psychiatry. 2014;26(4):270-280.
24. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277. doi:10.176/api.ajp.201.101704
25. Fava GA, Bech P. The Concept of Euthymia. Psychother Psychosom. 2016;85(1):1-5. doi:10.159/04124
26. Sakaue M, Ago Y, Sowa C, et al. Modulation by 5-hT2A receptors of aggressive behavior in isolated mice. Jpn J Pharmacol. 2002;89(1):89-92. doi:10.1254/jp.89.89
27. Tidey JW, Miczek KA. Effects of SKF 38393 and quinpirole on aggressive, motor and schedulecontrolled behaviors in mice. Behav Pharmacol. 1992;3(6):553-565. doi:10.1097/087-192120-03
28. Gendreau PL, Petitto JM, Petrova A, et al. D(3) and D(2) dopamine receptor agonists differentially modulate isolation-induced social-emotional reactivity in mice. Behav Brain Res. 2000;114(1-2):107-117. doi:10.1016/S016-4328(0)0193-5
29. Wang LY, Shofer JB, Rohde K, et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry. 2009;17(9):744-751. doi:10.1097/JGP.0b013e3181ab8c61
30. De Berardis D, Marini S, Serroni N, et al. Targeting the noradrenergic system in posttraumatic stress disorder: A systematic review and meta-Analysis of prazosin trials. Curr Drug Targets. 2015;16(10):1094-1106. doi:10.2174/13894501615050614108